The drive to tame gnawing hunger can sabotage even the best-intentioned dieter. Now, investigators have identified the brain circuit that underlies this powerful physiological state, providing a promising new target for the development of weight-loss drugs.
BOSTON – Air pollution, even at moderate levels, has long been recognized as a factor in raising the risk of stroke. A new study led by scientists from Beth Israel Deaconess Medical Center and Boston University School of Medicine suggests that long-term exposure can cause damage to brain structures and impair cognitive function in middle-aged and older adults.
As researchers are discovering that placebo responses are modified by a person's genetics, investigators from Beth Israel Deaconess Medical Center are raising questions as to how "the placebome" will impact both patient care and drug development.
Cancerous tumors have the ability to evade targeted therapies by activating alternative pathways. Tumors also contain cancer stem cells, believed responsible for metastasis and drug resistance. Now scientists in the Cancer Research Institute at Beth Israel Deaconess Medical Center have identified a drug target that addresses both of these challenges.
A new study from the Liver Center at Beth Israel Deaconess Medical Center (BIDMC) suggests that standard assessments that nurses already use to care for patients can be mined for data that significantly improve the ability to predict survival following liver transplantation and may help improve patient outcomes.
The search to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer is at the foundation of a new, cross-sector collaboration. Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach; the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC), a Harvard Medical School teaching hospital, and the Pancreatic Cancer Research Team (PCRT) managed by Cancer Research And Biostatistics (CRAB) announced today they will work together to eradicate the disease.
Because pseudogenes have lost the ability to code for proteins they have have long been considered nothing more than "genomic junk." Now, a team from the Cancer Research Institute at Beth Israel Deaconess Medical Center has discovered that one of these evolutionary relics caused an aggressive cancer, suggesting this "junk" may play a key role in disease.
BOSTON – Women with dense breast tissue are at increased risk of breast cancer. Dense breast tissue, generally defined as having more fibroglandular than fatty tissue, can make it more difficult for radiologists to detect cancer on screening mammography.
Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month’s Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration (FDA) panel convened last fall.
Beth Israel Deaconess Medical Center (BIDMC) has received a $450,000 grant from The Commonwealth Fund to develop OurNotes, an initiative to promote active patient engagement in health and illness that invites patients to contribute to their own electronic medical records.
A study led by investigators at Beth Israel Deaconess Medical Center has found that a vaccine that elicits only CD4 T cells resulted in an overwhelming inflammatory response in a mouse model of infection.
BOSTON – Each year more than 12 million Americans visit their doctors complaining of headaches, which result in lost productivity and costs of upward of $31 billion annually. A new study by researchers from Beth Israel Deaconess Medical Center (BIDMC) suggests some of that cost could be offset by physicians ordering fewer tests and an increased focus on counseling about lifestyle changes.
In studying the cellular structure and function of insulin, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has uncovered previously unknown steps in the development of insulin resistance, a hallmark of type 2 diabetes.
The Institute for Hepatobiliary and Pancreatic Surgery at Beth Israel Deaconess Medical Center (BIDMC) led by A. James Moser, MD, FACS, will benefit from a $100,000 grant from the Alliance of Families Fighting Pancreatic Cancer (AFFPC).
Project will focus on antibody repertoires and B cell diversity to better understand the role of the immune system in cardiovascular disease
George Tsokos, MD, Chief of Rheumatology at Beth Israel Deaconess Medical Center and a national leader in the field of lupus research was honored by both the Lupus Foundation and the American College of Rheumatology with two awards presented at the 2014 ACR Annual Scientific Meeting.
BOSTON – Charles Safran, MD, FACMI, Chief of the Division of Clinical Informatics at Beth Israel Deaconess Medical Center (BIDMC), has received the American College of Medical Informatics’ 2014 Morris F. Collen Award in recognition of his commitment to and achievements in medical informatics.
Treatment with 3TSR antiangiogenic agent is shown to regress tumors and improve effectiveness of chemotherapy in an animal model of ovarian cancer.
By exploiting a unique feature of the tumor microenvironment, scientists identify a novel delivery platform that leads to the inhibition of microRNA activity -- and the control of cancer growth
New findings support the possibility that, in the future, small, non-toxic doses of carbon monoxide could be used therapeutically to provide the immune system with an infection-fighting advantage.
Bruce Furie, MD, Chief of the Division of Hemostasis and Thrombosis at Beth Israel Deaconess Medical Center (BIDMC) has been named a 2014 Distinguished Scientist by the American Heart Association.
While osteoporosis prevention and treatment efforts have historically been focused on post-menopausal women, a new study from Beth Israel Deaconess Medical Center (BIDMC) suggests that critical opportunities are being lost by not focusing more attention on bone loss and fracture risk in older men.
A research team led by investigators at Beth Israel Deaconess Medical Center has identified an unexpected link between a transcription factor known to regulate speech and language development and metastatic colonization of breast cancer.
Investigators at Beth Israel Deaconess Medical Center have developed a brief and simple method to help hospital care providers recognize delirium in elderly patients
Elliot L. Chaikof, MD, PhD, Chair of the Roberta and Stephen R. Weiner Department of Surgery at Beth Israel Deaconess Medical Center (BIDMC) has been elected to the Institute of Medicine.
Researchers from Beth Israel Deaconess Medical Center report that the FGF21 hormone may be a reliable predictor of altered fructose metabolism and provide the basis for a "fructose tolerance test."
While it may take time before it’s known what impact email exchanges might have on patients and their care, a new study from Beth Israel Deaconess Medical Center (BIDMC) offers some early insights into the effects on doctors, suggesting that reimbursement models and physician workflow may need to adjust to accommodate message management.
The surprising discovery of a previously unidentified class of lipid molecules that enhance insulin sensitivity and blood sugar control offers a promising new avenue for the prevention and treatment of type 2 diabetes.
BIDMC has received a $20 million grant from the Bill & Melinda Gates Foundation to evaluate and test broadly neutralizing antibodies for the treatment of HIV.
A new study by investigators at Beth Israel Deaconess Medical Center suggests that brain networks -- the interconnected pathways that link brain circuits to one another -- can help guide site selection for brain stimulation therapies.
In a collaboration that will encompass a broad range of activities to advance cancer research and patient care and accelerate personalized genomic medicine, The Jackson Laboratory (JAX) and Beth Israel Deaconess Medical Center (BIDMC) have established a new academic, research and service relationship, the institutions’ presidents announced today.
Beth Israel Deaconess Medical Center has established a named professorship to celebrate the career of an internationally acclaimed cardiologist who developed new ways to correct life-threatening problems in the electrical system of the human heart.
Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient’s chances of having a long-term successful response to therapy, a pilot observational study at Beth Israel Deaconess Medical Center concludes.
Research led by investigators at Beth Israel Deaconess Medical Center helps explain the heat-generating properties of brown fat, a possible to key to weight loss.
The Institute for RNA Medicine, launched by the BIDMC Cancer Center, brings together leading investigators to pursue new lines of inquiry into non-coding RNA,.
Using a zebrafish model, investigators have identified a drug compound that appears to reverse arrhythmogenic cardiomyopathy, a hereditary disease and leading cause of sudden death in young people.
New findings from Beth Israel Deaconess Medical Center add a surprising new dimension to the understanding of antibody repertoires and their potential to better fight disease.
Important revelations regarding endothelial cell behavior are emerging from vascular simulation research, as highlighted in two recent papers from investigators at Beth Israel Deaconess Medical Center.
By linking cancer gene expression patterns with drug activity, a research team from Beth Israel Deaconess Medical Center finds a possible cancer therapy hidden in an antimicrobial agent.
Martin R. Pollak, MD, Chief of Nephrology at Beth Israel Deaconess Medical Center has been elected to the National Academy of Sciences.
Investigators at Beth Israel Deaconess Medical Center report a new mechanism by which BRCA gene loss may accelerate cancer-promoting chromosome rearrangements.
Ever since it was first identified more than 15 years ago, the PTEN gene has been known to play a key role in preventing the onset and progression of numerous cancers. New research from Beth Israel Deaconess Medical Center helps explain how.
BOSTON – Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.
A research team led by investigators at Beth Israel Deaconess Medical Center has found that targeting the enzyme responsible for the final step of glucose metabolism not only halts tumor growth in non-small-cell lung cancer, but actually leads to regression of established tumors.
By manipulating a biochemical process that underlies cells' energy-burning abilities, investigators at Beth Israel Deaconess Medical Center have made a novel discovery that could lead to a new therapy to combat obesity and diabetes.
Much has been reported about the potential for increased risk of alcohol misuse after weight loss surgery (WLS), with most theories pointing to lower alcohol tolerance and a longer time to return to a sober state after surgery, but a new study from Beth Israel Deaconess Medical Center suggests that upwards of half of high-risk drinkers are actually less likely to report high-risk drinking behavior after weight loss surgery.
BOSTON – Emergency department usage in Massachusetts rose slightly both during and immediately after implementation of a 2006 state law expanding health care access, a sign that broader availability of insurance may increase use of the ED, Beth Israel Deaconess Medical Center researchers report in a study published in the Annals of Emergency Medicine.
A research team from Beth Israel Deaconess Medical Center finds that the RBP4 protein acts like a foreign pathogen to trigger inflammation of fat tissue -- and diabetes risk.
BOSTON – Call it what you will – getting red in the face, hot under the collar, losing your cool, blowing your top – we all experience anger. And while we know that anger is a normal, sometimes even beneficial emotion, we‘re also aware of the often harmful connection between anger and health. New research from Beth Israel Deaconess Medical shows an even more compelling reason to think about getting anger in check – a nearly fivefold increase in risk for heart attack in the two hours following outbursts of anger.
A scientific team from Beth Israel Deaconess Medical Center has made a surprising discovery about the brain's hunger-inducing neurons, a finding with important implications for the treatment of obesity
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right